Top-performing Mass. biotech Corbus extends study of promising drug
Norwood-based Corbus Pharmaceuticals, the top-performing biotech stock in the state so far in 2016, said Tuesday that it will extend a Phase 2 study of its only drug in development.
Corbus (Nasdaq: CRBP) said that the FDA had approved a one-year, open-label extension study of the trial of anti-inflammatory drug Resunab to treat skin-predominant dermatomyositis. In April, the regulator approved a one-year extension study of Resunab for patients with systemic sclerosis. The com pany said in a statement… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - November 29, 2016 Category: Pharmaceuticals Authors: Max Stendahl Source Type: news
A Rash That Didn & #039;t Make Sense
It looked very much like dermatomyositis, but there were no signs of muscle weakness. What would be in your differential diagnosis? (Source: ConsultantLive)
Source: ConsultantLive - November 4, 2016 Category: Internal Medicine Authors: Jonathan A. Schneider, DO Tags: Special Report Skin Diseases Source Type: news
SHARE initiative releases consensus-based JDM management recommendations
Early and aggressive therapy may prevent or stabilize organ damage and disease-related complications in patients with juvenile dermatomyositis, according to new consensus-based recommendations for the management of the disorder.
Overall, the recommendations – a project of the Single Hub and Access... (Source: Skin and Allergy News)
Source: Skin and Allergy News - August 26, 2016 Category: Dermatology Source Type: news
VIDEO: TNF inhibitors improved refractory skin disease in juvenile dermatomyositis
LONDON – Tumor necrosis factor–inhibitor treatment improved refractory skin disease in juvenile dermatomyositis patients in the largest observational study of its kind from the United Kingdom and... (Source: Pediatric News)
Source: Pediatric News - June 27, 2016 Category: Journals (General) Source Type: news
VIDEO: TNF inhibitors improved refractory skin disease in juvenile dermatomyositis
LONDON – Tumor necrosis factor–inhibitor treatment improved refractory skin disease in juvenile dermatomyositis patients in the largest observational study of its kind from the United Kingdom and Ireland Juvenile Dermatomyositis Research Group.
Muscle disease in the juvenile dermatomyositis (JDM)... (Source: Skin and Allergy News)
Source: Skin and Allergy News - June 27, 2016 Category: Dermatology Source Type: news
TNF Blockers Treat Muscles, Skin in Juvenile DermatomyositisTNF Blockers Treat Muscles, Skin in Juvenile Dermatomyositis
Anti-tumor necrosis factor (TNF) agents are showing promise for the rare childhood autoimmune disorder, juvenile dermatomyositis, new research shows. Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - June 16, 2016 Category: Allergy & Immunology Tags: Rheumatology News Source Type: news
New treatment offers hope for children with debilitating skin and muscle disease
The results of a UK study showed that tumor necrosis factor inhibitor treatment is effective at improving both muscle and skin involvement in children with juvenile dermatomyositis (JDM). These findings bring new hope to JDM patients who have failed to respond to multiple drug treatments and who, as a result, have a greater risk of painful complications and premature death. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - June 10, 2016 Category: Science Source Type: news
New treatment offers hope for children with debilitating skin and muscle disease
(European League Against Rheumatism) The results of a UK study presented today at the European League Against Rheumatism Annual Congress showed that tumor necrosis factor inhibitor treatment is effective at improving both muscle and skin involvement in children with juvenile dermatomyositis (JDM). These findings bring new hope to JDM patients who have failed to respond to multiple drug treatments and who, as a result, have a greater risk of painful complications and premature death. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 10, 2016 Category: Global & Universal Source Type: news
Dermatomyositis Quiz: 8 Key Questions
Take this quick quiz to test your knowledge of a relatively uncommon inflammatory muscle disease. (Source: ConsultantLive)
Source: ConsultantLive - June 2, 2016 Category: Internal Medicine Authors: Leo Robert Tags: Quiz Skin Diseases Source Type: news
Tofacitinib an alternative treatment for refractory cutaneous dermatomyositis
Tofacitinib, an oral Janus kinase (JAK)-1/3 inhibitor approved for treating rheumatoid arthritis, was beneficial in treating cutaneous dermatomyositis in three patients who had failed traditional therapies, according to a report published in JAMA Dermatology.
Dr. Drew J.B. Kurtzman of the... (Source: Skin and Allergy News)
Source: Skin and Allergy News - May 4, 2016 Category: Dermatology Source Type: news
Dermatomyositis As a Prodromal Sign of Lung AdenocarcinomaDermatomyositis As a Prodromal Sign of Lung Adenocarcinoma
This case report highlights the importance of a thorough search for underlying malignancy in patients with dermatomyositis. Journal of Medical Case Reports (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - April 11, 2016 Category: Allergy & Immunology Tags: Dermatology Journal Article Source Type: news
Shiitake happens: dermatitis from uncooked mushrooms
puttography/shutterstock.com
3.5 out of 5 stars
Shiitake dermatitis: the tale of an under-recognised, undercooked fungus. McNally A et al. Med J Aust 2016 Feb 15;204:124-6
Reference
Just when you thought it was safe to go back to the farmers’ market . . .
This interesting paper presents a series of 3 cases of flagellate dermatitis following consumption of raw or undercooked shiitake mushrooms. The rashes described were linear, pruritic, and papular, sparing areas such as the mid-back that could not be reached for scratching. All of these factors suggested that lesions were caused by the Koebner phenomenon.
S...
Source: The Poison Review - February 20, 2016 Category: Toxicology Authors: Leon Tags: Medical flagellate dermatitis lentinan mushroom poisoning shiitake Source Type: news
Heart Rate Variability Lowered in JDM Patients (CME/CE)
(MedPage Today) -- Finding suggests reduced vagal control over the heart in juvenile dermatomyositis (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - November 9, 2015 Category: Cardiology Source Type: news
Polymyositis/Dermatomyositis Associated With High Rate of Diastolic Dysfunction (CME/CE)
(MedPage Today) -- Inflammation appears to be underlying pathology (Source: MedPage Today Rheumatology)
Source: MedPage Today Rheumatology - November 6, 2015 Category: Rheumatology Source Type: news
